• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 528 名患有精神分裂症且严重受损的患者中,使用氨磺必利治疗,早期和延迟的抗精神病反应与结局预测。

Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.

机构信息

Psychosis Early Detection and Intervention Centre (PEDIC), Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf.

出版信息

Pharmacopsychiatry. 2009 Nov;42(6):277-83. doi: 10.1055/s-0029-1234105. Epub 2009 Nov 18.

DOI:10.1055/s-0029-1234105
PMID:19924588
Abstract

INTRODUCTION

'Early-onset' studies have shown that symptomatic response often occurs early and that early symptomatic response is predictive for later outcome. Limiting factors of these studies include the restriction on symptomatic outcome, the inclusion of mostly moderately ill patients, and the use of various antipsychotics.

METHODS

Response and remission rates were assessed in 528 severely ill patients with schizophrenia at baseline, week 2, 4 and 12 using PANSS, SWN-K, CGI-S, and SOFAS. The clinical measures were combined to one outcome criterion (CombOut). Predicitive validity was analyzed for CombOut using linear regression models.

RESULTS

Rate and time to response differed markedly between outcome measures. 32% reached positive symptom response at week 2, 58% at week 4 and 85% at week 12. Non-response at week 4, but not at week 2 was predictive for later non-response. The combined outcome criterion was best predicted by early response in subjective wellbeing (T=-7.88, p<0.001) and social functioning (T=-7.43, p<0.001).

DISCUSSION

Rate and time to response might depend on sample characteristics and outcome measure. In severely ill patients early antipsychotic response is possibly delayed from the first 2 to the first 4 weeks. Early response in subjective wellbeing and social functioning are strong predictors for overall outcome, which make them a useful supplementation to the assessment of symptomatic response.

摘要

简介

“早期发病”的研究表明,症状缓解通常发生得较早,且早期症状缓解可预测后期结果。这些研究的限制因素包括对症状缓解的限制,主要纳入中度病情患者,以及使用各种抗精神病药物。

方法

使用 PANSS、SWN-K、CGI-S 和 SOFAS 在基线、第 2、4 和 12 周评估 528 名严重精神分裂症患者的缓解率和缓解率。将临床测量值组合为一个结果标准(CombOut)。使用线性回归模型分析 CombOut 的预测有效性。

结果

不同的结果测量标准中,缓解率和缓解时间差异明显。2 周时有 32%的患者达到阳性症状缓解,4 周时有 58%,12 周时有 85%。4 周时无缓解,但 2 周时无缓解预测后期无缓解。早期的主观幸福感(T=-7.88,p<0.001)和社会功能(T=-7.43,p<0.001)反应是综合结果标准的最佳预测指标。

讨论

缓解率和缓解时间可能取决于样本特征和结果测量。在严重的患者中,早期抗精神病药物的反应可能从第 2 周延迟到第 4 周。主观幸福感和社会功能的早期反应是整体结果的有力预测指标,这使其成为症状缓解评估的有用补充。

相似文献

1
Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.在 528 名患有精神分裂症且严重受损的患者中,使用氨磺必利治疗,早期和延迟的抗精神病反应与结局预测。
Pharmacopsychiatry. 2009 Nov;42(6):277-83. doi: 10.1055/s-0029-1234105. Epub 2009 Nov 18.
2
Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride.使用氨磺必利治疗的727例精神分裂症患者严重受损的主观幸福感得到缓解。
Acta Psychiatr Scand. 2007 Feb;115(2):106-13. doi: 10.1111/j.1600-0447.2006.00862.x.
3
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?精神分裂症和精神分裂症谱系障碍的生活质量和主观幸福感:症状反应和缓解的有效预测因子?
World J Biol Psychiatry. 2010 Aug;11(5):729-38. doi: 10.3109/15622971003690289.
4
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.齐拉西酮和阿立哌唑有效治疗精神分裂症的阴性症状:一项为期12周的双盲研究结果。 你提供的原文中药物名称有误,正确的应该是齐拉西酮(Ziprasidone)和阿立哌唑(Aripiprazole),我按照正确的药物名称进行了翻译。若按照你给定的原文“Ziprasidone and amisulpride”翻译,译文为“齐拉西酮和氨磺必利有效治疗精神分裂症的阴性症状:一项为期12周的双盲研究结果” 。
Int Clin Psychopharmacol. 2006 May;21(3):143-51. doi: 10.1097/01.yic.0000182121.59296.70.
5
Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia.主观幸福感的改善与持久症状缓解:首发精神分裂症的5年随访
Pharmacopsychiatry. 2008 Jul;41(4):125-8. doi: 10.1055/s-2008-1076729.
6
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.精神分裂症的缓解:对精神分裂症或分裂情感性障碍患者使用利培酮长效注射剂(RLAI)的意大利为期一年的前瞻性研究。
Hum Psychopharmacol. 2009 Oct;24(7):574-83. doi: 10.1002/hup.1067.
7
Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.抗抑郁药引发的早期改善能否预测疗效/缓解情况?对大量重度抑郁症住院患者的自然主义研究数据进行分析。
J Affect Disord. 2009 Jun;115(3):439-49. doi: 10.1016/j.jad.2008.10.011. Epub 2008 Nov 22.
8
Amisulpride: a review of its efficacy in schizophrenia.氨磺必利:对其治疗精神分裂症疗效的综述
Acta Psychiatr Scand Suppl. 2000;400:17-22.
9
Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.氨磺必利对氯氮平部分反应或无反应的精神分裂症患者的增效作用。一项随机、双盲、安慰剂对照试验。
Pharmacopsychiatry. 2008 Jan;41(1):24-8. doi: 10.1055/s-2007-993209.
10
Achieving symptomatic remission in out-patients with schizophrenia--a naturalistic study with quetiapine.使用喹硫平对门诊精神分裂症患者实现症状缓解——一项自然主义研究
Acta Psychiatr Scand. 2009 Aug;120(2):120-8. doi: 10.1111/j.1600-0447.2009.01379.x. Epub 2009 Mar 11.

引用本文的文献

1
Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia.长期住院慢性精神分裂症患者健康相关生活质量的相关因素。
PCN Rep. 2022 Sep 8;1(3):e42. doi: 10.1002/pcn5.42. eCollection 2022 Sep.
2
The role of pharmacists in supporting service users to optimise antipsychotic medication.药师在支持服务使用者优化抗精神病药物治疗方面的作用。
Int J Clin Pharm. 2023 Oct;45(5):1293-1298. doi: 10.1007/s11096-023-01630-9. Epub 2023 Sep 13.
3
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.
早期无应答可预测精神分裂症患者对抗精神病药物的后期无应答:一项随机试验。
BMC Med. 2023 Jul 19;21(1):263. doi: 10.1186/s12916-023-02968-7.
4
Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: a real-world study.初治及未使用过药物的精神分裂症患者早期无反应的发生率及相关因素:一项真实世界研究
Front Psychiatry. 2023 Apr 27;14:1173263. doi: 10.3389/fpsyt.2023.1173263. eCollection 2023.
5
Estimation of subjective quality of life in schizophrenic patients using speech features.利用语音特征评估精神分裂症患者的主观生活质量
Front Rehabil Sci. 2023 Mar 10;4:1121034. doi: 10.3389/fresc.2023.1121034. eCollection 2023.
6
Resilience and Quality of Life in People with Mental Illness: A Systematic Review and Meta-Analysis.精神疾病患者的心理韧性与生活质量:一项系统综述与荟萃分析
Neuropsychiatr Dis Treat. 2023 Mar 4;19:507-514. doi: 10.2147/NDT.S392332. eCollection 2023.
7
Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders.用氨磺必利优化首发精神分裂症或相关障碍患者的主观幸福感。
Psychol Med. 2023 Oct;53(13):5986-5991. doi: 10.1017/S0033291722003142. Epub 2022 Dec 15.
8
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.在一项大规模随机对照试验中,第 2 周的抗精神病药物早期疗效可预测第 6 周的后续反应。
Curr Neuropharmacol. 2023;21(2):424-436. doi: 10.2174/1570159X21666221118164612.
9
Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".日本神经精神药理学学会:《精神分裂症药物治疗指南》
Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324. doi: 10.1002/npr2.12193. Epub 2021 Aug 12.
10
Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia.精神分裂症患者的认知差异、动机与主观幸福感
Schizophr Res Cogn. 2021 Jun 30;26:100205. doi: 10.1016/j.scog.2021.100205. eCollection 2021 Dec.